What inspired the theme “‘Driven by Biology, Centred on the Person: A New Approach to Head and Neck Cancer’” for ICHNO 2026, and why do you think this approach is important for head and neck oncology?

I believe modern oncology is rapidly moving toward a future where biological insights will increasingly allow us to define the disease’s care profile with greater precision, while a strong focus on the individual will enable us to tailor therapeutic models to each patient. This dual perspective—biologically driven and person-centred—is, in my view, essential for truly personalised care in head-and-neck oncology.

How does the collaboration between ESTRO, EHNS, and ESMO enhance the congress and benefit attendees?

The collaboration between ESTRO, EHNS, and ESMO ensures the highest level of multidisciplinary discussion of the topics that will be addressed during the congress. This synergy makes it possible to integrate different perspectives and expertise, offering a comprehensive and up-to-date overview of the latest advances in oncology and an in-depth discussion of the key issues for the care of patients with head-and-neck cancers.

What are some of the most exciting innovations or research topics that participants can expect to learn about at this congress?

Certainly, a significant focus will be dedicated to exploring all the facets of immuno-oncology (IO) in both neoadjuvant and adjuvant settings. The congress will provide an in-depth look at the latest data, ongoing trials, and practical considerations for integrating IO into multidisciplinary management of head-and-neck cancers. Attendees can expect comprehensive sessions that address the challenges and opportunities of IO, including patient selection, biomarkers, therapeutic combinations, and the translation of emerging evidence into clinical practice

How does ICHNO 2026 aim to facilitate multidisciplinary collaboration, and why is this important for advancing patient care in head and neck oncology?

Multidisciplinary collaboration has become an indispensable added value in the management of head-and-neck cancers. This is especially true as new data increasingly demonstrate the potential and significant advantages offered by advanced therapeutic approaches. By bringing together specialists from different fields, we ensure that each patient benefits from integrated expertise, leading to more informed decision-making and the best possible outcomes. The convergence of various perspectives fosters innovation and accelerates the translation of groundbreaking research into clinical practice, ultimately raising the standard of care for all patients.

What message would you like to share with potential attendees about the value of joining this congress in Seville?

 Attending this congress in the magnificent setting of Seville is truly unmissable for those wishing to keep pace with the most innovative and authentic advances in head-and-neck oncology. Here, participants will have the opportunity to engage with leading experts, discover breakthrough research, and actively shape the future of multidisciplinary care. The rich scientific programme, combined with the inspiring atmosphere of Seville, creates the ideal environment for meaningful exchange, collaboration, and professional growth.

Why should researchers and clinicians submit an abstract to ICHNO 2026?

 Scientific progress relies on the collective contributions of researchers and clinicians from every discipline and background. The only way to truly take part in shaping this meeting is to share your own research findings and clinical experiences by submitting an abstract. Now, more than ever, our strength lies in unity—by coming together, by acting in a multidisciplinary manner, we unlock the greatest potential for discovery and advancement. United, we can meet the challenges ahead and achieve meaningful victories for our patients and our field.

Professor Giovanni Succo

ENHS Chair for ICHNO 2026

Submission of Abstracts deadline: 8 October 2025